Geschäftskunden Kundenprogramme
Vor Ort
Merkzettel Warenkorb
Produktbild: Crystallization of Organic Compounds

Crystallization of Organic Compounds An Industrial Perspective

Fr. 156.00

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

01.06.2009

Verlag

John Wiley & Sons Inc

Seitenzahl

290

Maße (L/B/H)

26/18.4/2.7 cm

Gewicht

683 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-0-471-46780-9

Beschreibung

Rezension

"For chemists and engineers working in process research and development, or even in production, this is the best book on crystallisation. For those in other disciplines, or in academia, wishing to get a perspective on industrial problems in crystallisation, polymorphism, salt formation etc and how to solve them, this would also be a valuable book . . . I think they have achieved both of these goals admirably, and in a very readable and enjoyable format." (Organic Process, Research & Development Journal, 17 December 2010)

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

01.06.2009

Verlag

John Wiley & Sons Inc

Seitenzahl

290

Maße (L/B/H)

26/18.4/2.7 cm

Gewicht

683 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-0-471-46780-9

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern
Die Leseprobe wird geladen.
  • Produktbild: Crystallization of Organic Compounds
  • Preface.
    1. Introduction to Crystallization Issues.

    1.1 Crystal Properties and Polymorphism (Chapters 2 and 3).

    1.2 Nucleation and Growth Kinetics (Chapter 4).

    1.3 Critical Issues (Chapter 5).

    1.4 Mixing and Crystallization (Chapter 6).

    1.5 Crystallization Process Options (Chapters 7-10).

    1.6 Special Applications (Chapter 11).

    1.7 Regulatory Issues.

    2. Properties.

    2.1 Solubility.

    2.2 Supersaturation, Metastable Zone, and Induction Time.

    2.3 Oil, Amorphous, and Crystalline States.

    2.4 Polymorphism.

    2.5 Solvate.

    2.6 Solid Compound, Solid Solution, and Solid Mixture.

    2.7 Inclusion and Occlusion.

    2.8 Adsorption, Hygroscopicity, and Deliquescence.

    2.9 Crystal Morphology.

    2.10 Particle Size Distribution and Surface Area.

    3. Polymorphism.

    3.1 Phase Rule.

    3.2 Phase Transition.

    3.3 Examples.

    Example 3-1 Indomethacin.

    Example 3-2 Sulindac.

    Example 3-3 Losartan.

    Example 3-4 Finasteride.

    Example 3-5 Ibuprofen Lysinate.

    Example 3-6 HCl Salt of a Drug Candidate.

    Example 3-7 Second HCl Salt of a Drug Candidate.

    Example 3-8 Prednisolone t-Butylacetate.

    Example 3-9 Phthalylsulfathiazole.

    3.4 Future Direction.

    4. Kinetics.

    4.1 Supersaturation and Rate Processes.

    4.2 Nucleation.

    4.3 Crystal Growth.

    4.4 Nucleate/Seed Aging and Ostwald Ripening.

    4.5 Delivered Product: Size Distribution and Morphology.

    5. Critical Issues in Crystallization Practice.

    5.1 Introduction.

    5.2 Nucleation.

    5.3 Growth.

    5.4 Oiling Out, Agglomeration/Aggregation.

    5.5 Seeding.

    5.6 Rate of Generation of Supersaturation.

    5.7 Summary of Critical Issues.

    6. Mixing and Crystallization.

    6.1 Introduction.

    6.2 Mixing Considerations.

    6.3 Mixing Effects on Nucleation.

    6.4 Mixing Effects on Crystal Growth.

    6.5 Mixing Scale-up.

    6.6 Crystallization Equipment.

    Example 6-1.

    7. Cooling Crystallization.

    7.1 Batch Operation.

    7.2 Continuous Operations.

    7.3 Process Design-Examples.

    Example 7-1 Intermediate in a Multistep Synthesis.

    Example 7-2 Pure Crystallization of an API.

    Example 7-3 Crystallization Using the Heel from the Previous Batch as Seed.

    Example 7-4 Resolution of Ibuprofen Via Stereospecific Crystallization.

    Example 7-5 Crystallization of Pure Bulk with Polymorphism.

    Example 7-6 Continuous Separation of Stereoisomers.

    8. Evaporative Crystallization.

    8.1 Introduction.

    8.2 Solubility Diagrams.

    8.3 Factors Affecting Nucleation and Growth.

    8.4 Scale-up 171

    8.5 Equipment.

    Example 8-1 Crystallization of a Pharmaceutical Intermediate Salt.

    Example 8-2 Crystallization of the Sodium Salt of a Drug Candidate.

    9. Antisolvent Crystallization.

    9.1 Semibatch Operation.

    Example 9-1 Crystallization of an Intermediate.

    Example 9-2 Rejection of Isomeric Impurities of Final Bulk Active Product.

    Example 9-3 Crystallization of a Pharmaceutical Product with Poor Nucleation and Growth Characteristics.

    Example 9-4 Impact of Solvent and Supersaturation on Particle Size and Crystal Form.

    9.2 In-Line Mixing Crystallization.

    Example 9-5 Crystallization of an API Using Impinging Jets.

    Example 9-6 Crystallization of a Pharmaceutical Product Candidate Using an Impinging Jet with Recycle.

    10. Reactive Crystallization.

    10.1 Introduction.

    10.2 Control of Particle Size.

    10.3 Key Issues in Organic Reactive Crystallization.

    10.4 Scale-up.

    Example 10-1 Reactive Crystallization of an API.

    Example 10-2 Reactive Crystallization of an Intermediate.

    Example 10-3 Reactive Crystallization of a Sodium Salt of an API.

    Example 10-4 Reactive Crystallization of an API.

    10.5 Creation of Fine Particles-In-Line Reactive Crystallization.

    11. Special Applications.

    11.1 Introduction.

    11.2 Crystallization with Supercritical Fluids.

    11.3 Ultrasound in Crystallization.

    11.4 Computational Fluid Dynamics in Crystallization.

    Example 11-1 Sterile Crystallizat